Remibrutinib Shows Early CSU Symptom Relief
REMIBRUTINIB improved itch and hive severity within 12 hours in chronic spontaneous urticaria in Phase III analysis.
A pooled analysis of the Phase III REMIX I and REMIX II studies suggests remibrutinib may provide rapid symptom relief for patients with chronic spontaneous urticaria. Investigators assessed daily Hives Severity Scores and Itch Severity Scores to better characterize the onset of efficacy during the first week of treatment.
The analysis included 606 patients who received oral remibrutinib 25 mg twice daily and 306 who received placebo. Chronic spontaneous urticaria disease activity was measured using the Urticaria Activity Score, which combines Hives Severity Score and Itch Severity Score. Daily scores were calculated as the average of morning and evening assessments, apart from Day 1, when only evening scores taken 12 hours after dosing were used.
Remibrutinib in Chronic Spontaneous Urticaria
At baseline, very few patients in either treatment arm were in the lowest severity bands for hives or itch. In the remibrutinib arm, 1.2% of patients had a Hives Severity Score of 0 and 0.5% had an Itch Severity Score of 0. In the placebo arm, 0.7% of patients were in each of these lowest bands.
Within the first 12 hours, a greater proportion of patients receiving remibrutinib shifted into complete absence of hives and itch compared with placebo. For hives, 5.8% of patients in the remibrutinib arm reached a Hives Severity Score of 0 versus 2.4% in the placebo arm. For itch, 5.1% versus 2.7% reached an Itch Severity Score of 0.
Symptom Control Sustained Through Day 7
This early separation from placebo was sustained through Day 7. By the end of the first week, 33.8% of patients treated with remibrutinib were in the lowest hives severity band compared with 7.0% of patients receiving placebo. Similarly, 27.3% of the remibrutinib arm had no itch by Day 7 compared with 5.0% of the placebo arm.
These findings suggest remibrutinib was associated with a rapid and sustained shift toward complete symptom control over the first 7 days of treatment. For clinicians managing chronic spontaneous urticaria, the speed of improvement in itch and hives may be especially relevant given the burden of daily symptoms and their effect on quality of life.
Early Improvement Across Key Symptom Measures
The analysis adds further detail to the efficacy profile of remibrutinib by focusing on daily symptom scores rather than broader weekly summaries alone. The proportion of patients reaching no hives or no itch within 12 hours, and maintaining higher rates of complete symptom control through Day 7, highlights the potential for early treatment benefit in chronic spontaneous urticaria.
Overall, patients receiving remibrutinib were more likely than those receiving placebo to achieve the lowest Hives Severity Score and Itch Severity Score bands from the first post dose assessment onward. The findings support a rapid onset of action across key patient reported symptom measures in chronic spontaneous urticaria.
Reference
Metz M et al. Early symptom improvement with remibrutinib in chronic spontaneous urticaria: Daily Itch Severity Scores and Hives Severity Scores from Phase III REMIX I/II studies. Abstract 6445. AAD Annual Meeting, 27-31 March, 2026.
Featured image: 9nong on Adobe Stock.
